Safety of GM-CSF in patients with AIDS: A review of the literature

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1290-1297

  Ross, Susan D ^a   DiGeorge, Angela ^a   Connelly, Janet E ^a   Whiting, Gregory W ^a   McDonnell, Neil ^b  

^a MetaWorks Inc   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CANCER RISK; DATA ANALYSIS; DRUG SAFETY; HUMAN; INCIDENCE; OPPORTUNISTIC INFECTION; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CLINICAL TRIALS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV; HUMANS; TREATMENT OUTCOME;

EID: 0031783774     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Capetti A, Bonfanti P, Magni C, Milazzo F. Employment of recombinant human granulocyte-macrophage colony stimulating factor in oesophageal candidiasis in AIDS patients. AIDS 1995;9:1378-9.
2. Kemper C, Bermudez L, Agosti J, Deresinski S. Immuno-modulatory therapy of Mycobacterium avium (MAC) bacteremia in AIDS with rhGM-CSF. In: Abstracts of the 35th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: American Society of Microbiology, 1995:177.
3. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987;238:800-2.
4. Perno CF, Cooney DA, Gao WY, et al. Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood 1992;80:995-1003.
5. Novak RM, Holzer TI, Kennedy MM, Heynen CA, Dawson G. The effects of interleukin 4 (BSF-1) on infection of peripheral blood monocyte-derived macrophages with HIV-1. AIDS Res Hum Retrovirus 1990;6:973-6.
6. Kitano K, Abboud CN, Ryan DH, Quan SG, Baldwin GC, Golde DW. Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells. Blood 1991;77:1699-1705.
7. Hammer SM, Gillis JM, Pinkson P, Rose RM. Effect of zidovudine and granulocyte-macrophage colony stimulating factor on human immunodeficiency virus replication in alveolar macrophages. Blood 1990;75:1215-19.
8. Lebargy F, Branellec A, Deforges L, Bignon J, Bernaudin JF. HIV-1 in human alveolar macrophages from infected patients is latent in vivo but replicates after in vitro stimulation. Am J Respir Cell Mol Biol 1994;10:72-6.
9. Hammer SM, Gillis JM, Groopman JE, Rose RM. In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon. Proc Natl Acad Sci USA 1986;83:8734-8.
10. Matsuda S, Akagawa K, Honda M, Yokota Y, Takebe Y, Takemori T. Suppression of HIV replication in human monocyte-derived macrophages induced by granulocyte/macrophage colony-stimulating factor. AIDS Res Hum Retrovirus 1995;11:1031-8.
11. Hammer SM, Gillis JM. Synergistic activity of granulocyte macrophage colony-stimulating factor and 3′-azido-3′deoxythymidine against human immunodeficiency virus in vitro. Antmicrob Agents Chemother 1987;31:1046-50.
12. Perno CF, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/ macrophage colony stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2′3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989;169:933-51.
13. Sacks HS, Berrier J, Reitman D, Ancona-Berk V, Chalmers T. Meta-analyses of randomized controlled trials. N Engl J Med 1987;316:450-5.
14. Sacks HS, Berrier J, Reitman D, Pagano D, Chalmers T. Meta-analyses of randomized control trials: an update of the quality and methodology. In: Bailar JC III, Mosteller F, eds. Medical uses of statistics, 2nd ed. Boston: New England Journal of Medicine Books, 1992:427-42.
15. Chalmers TC, Lau J. Meta-analytic stimulus for changes in clinical trials. Stat Methods Med Res 1993;2:161-72.
16. Jadad AR. Meta-analysis of randomised clinical trials in pain relief. D.Phil thesis, Balliol College, University of Oxford, United Kingdom, 1994.
17. Chalmers I, Altman DG, eds. Systematic reviews. London: BMJ Publishing Group, 1995.
18. Mulrow CD, Oxman AD, eds. Cochrane collaboration handbook. Oxford: Cochrane Collaboration, 1997.
19. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
20. Bakker PJ, Danner SA, ten Napel CH, et al. Treatment of poor prognosis epidemic Kaposi's sarcoma with doxorubicin, bleomycin, vindesine and recombinant human granulocytemonocyte colony stimulating factor (rh GM-CSF). Eur J Cancer 1995;31A:188-92.
21. Boente P, Sampaio C, Brandao MA, Moreira ED, Badaro R, Jones TC. Local peri-lesional therapy with rhGM-CSF for Kaposi's sarcoma [letter]. Lancet 1993;341:1154.
22. Gill PS, Bernstein-Singer M, Espina BM, et al. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma. AIDS 1992;6:1477-81.
23. Hermans P, Gori A, Lemone M, Franchioly P, Clumeck N. Possible role of granulocyte-macrophage colony stimulating factor (GM-CSF) on the rapid progression of AIDS-related Kaposi's sarcoma lesions in vivo. Br J Haematol 1994;87: 413-14.
24. Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991;9:929-40.
25. Krown SE, Paredes J, Bundow D, Polsky B, Gold JW, Flomenberg N. Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS clinical trials group study in patients with Kaposi's sarcoma associated with AIDS. J. Clin Oncol 1992;10:1344-51.
26. Scadden DT, Bering HA, Levine JD, et al. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991;9:802-8 [published erratum appears in J Clin Oncol 1992;10(2):346.].
27. Scadden DT, Bering HA, Levine JD, et al. GM-CSF as an alternative to dose modification of the combination zidovudine and interferon-alpha in the treatment of AIDS-associated Kaposi's sarcoma. Am J Clin Oncol 1991;14(suppl 1):S40-4.
28. Walsh C, Wernz JC, Levine A, et al. Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 1993;6:265-71.
29. Hardy WD. Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. J Acquir Immune Defic Syndr 1991;4(suppl 1):S22-8.
30. Aweeka FT, Mak M, Aluzri A, et al. Oral and intravenous zidovudine pharmacokinetics - the effect of granulocyte-macrophage colony stimulating factor. J Clin Pharmacol 1995;35:856-64.
31. Baldwin GC, Gasson JC, Quan SG, et al. Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. Proc Natl Acad Sci USA 1988;85:2763-6.
32. Davey RT, Davey VJ, Metcalf JA, et al. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 1991;164:43-52.
33. Davison FD, Kaczmarski RS, Pozniak A, Mufti GJ, Sutherland S. Quantification of HIV by PCR in monocytes and lymphocytes in patients receiving antiviral treatment and low dose recombinant human granulocyte macrophage colony-stimulating factor. J Clin Pathol 1994;47:855-7.
34. Groopman JE, Mitsuyasu RT, Deleom J, Oette D, Golde DW. Effect of recombinant human GM-CSF on myelopoiesis in acquired immunodeficiency syndrome. N Engl J Med 1987;317:593-8.
35. Hewitt RG, Morse GD, Lawrence WD, et al. Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex. Antimicrob Agents Chemother 1993;37:512-22.
36. Kaczmarski RS, Pozniak A, Lakham A, Harvey E, Mufti GJ. A pilot study of low-dose recombinant human granulocyte-macrophage colony-stimulating factor in chronic neutropenia. Br J Haematol 1993;84:338-40.
37. Lafeuillade A, Tamalet C, Pellegrino P, Tourres C, Vignoli C, Quilichini R. HIV-1 viraemia during granulocyte-macrophage colony stimulating factor therapy [letter]. AIDS 1992;6:1550-1.
38. Levine JD, Allan JD, Tessitore JH, et al. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex. Blood 1991;78:3148-54.
39. Manfredi R, Cariani T, Latini, F, Chiodo F. Recombinant granulocyte-macrophage colony-stimulating factor in the treatment of HIV-related leucopenia. Acta Paediatr 1995;84:943-4.
40. Pluda JM, Yarchoan R, Smith PD, et al. Subcutaneous recombinant GM-CSF used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe HIV infection. Blood 1990;76:463-72.
41. Scadden DT, Pickus O, Hammer SM, et al. Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type I. AIDS Res Hum Retroviruses 1996;12:1151-9.
42. Eduardo L, Bermudez M, Young LS. Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukocyte Biol 1990;48:67-73.
43. Ganser A, Greher J, Volkers B, Staszewski S, Hoelzer D. Inhibitory effect of azidothymidine, 2′-3′-dideoxyadenosine, and 2′-3′-dideoxycytidine on in vitro growth of hematopoietic progenitor cells from normal persons and from patients with aids. Exp Hematol 1989;17:321-5.
44. Ganser A, Volkers B, Greher J, Hoelzer D. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on the hemopoietic progenitor cells from patients with AIDS. Behring Inst Mitt 1988;83:284-8.
45. Israel RJ, Levine JD. Granulocyte-macrophage colony-stimulating factor and azidothymidine in patients with acquired immunodeficiency syndrome [letter; comment]. Blood 1991;77:2085-7.
46. Scadden D, Pinkus O, Hammer S, et al. In vivo effects of combined GM-CSF and AZT in patients with HIV disease. Blood 1995;86(suppl 1):934a.
47. Sulecki M, Rosenfield C, Przepiorka D, Bloom E, Buhles W, Shadduck R. Treatment of ganciclovir-induced neutropenia with recombinant human GM-CSF. Am J Med 1991;90:401-2.
48. Tirelli U, Sorio R, Monfardini S, Lazzarin A, Rossi G, Mazzanti P. Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with AIDS-related tumors and chemotherapy-induced bone-marrow suppression [letter]. J Acquir Immune Defic Syndr 1990;3(11):1115.
49. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-9.
50. Ross SD, Allen IA, Luo D, et al. Systematic overview and meta-analysis of published and unpublished trials of GM-CSF in prevention of chemotherapy-induced neutropenia (CIN). Report to Immunex Corporation. November, 1996.